MCID: LKM002
MIFTS: 65

Leukemia

Categories: Blood diseases, Bone diseases, Cancer diseases, Immune diseases
Data Licensing
For inquiries, contact:

Aliases & Classifications for Leukemia

MalaCards integrated aliases for Leukemia:

Name: Leukemia 11 75 28 53 41 43 14 36 16 71
Leukaemia, Unspecified, Without Mention of Remission 33
Aleukemic Leukaemia 33
Subacute Leukaemia 33
Leukaemia Disorder 33
Chronic Leukaemia 33
Leukaemia Nos 33
Leukemias 14

Classifications:



External Ids:

Disease Ontology 11 DOID:1240
ICD9CM 34 208
MeSH 43 D007938
NCIt 49 C3161
SNOMED-CT 68 255049003
ICD10 31 C94.7 C95.9
ICD11 33 1385484871
UMLS 71 C0023418

Summaries for Leukemia

MedlinePlus: 41 What is leukemia? Leukemia is a term for cancers of the blood cells. Leukemia starts in blood-forming tissues such as the bone marrow. Your bone marrow makes the cells which will develop into white blood cells, red blood cells, and platelets. Each type of cell has a different job: White blood cells help your body fight infection Red blood cells deliver oxygen from your lungs to your tissues and organs Platelets help form clots to stop bleeding When you have leukemia, your bone marrow makes large numbers of abnormal cells. This problem most often happens with white blood cells. These abnormal cells build up in your bone marrow and blood. They crowd out the healthy blood cells and make it hard for your cells and blood to do their work. What are the types of leukemia? There are different types of leukemia. Which type of leukemia you have depends on the type of blood cell that becomes cancer and whether it grows quickly or slowly. The type of blood cell could be: Lymphocytes, a type of white blood cell Myeloid cells, immature cells that become white blood cells, red blood cells, or platelets The different types can grow quickly or slowly: Acute leukemia is fast growing. It usually gets worse quickly if it's not treated. Chronic leukemia is slow growing. It usually gets worse over a longer period of time. The main types of leukemia are: Acute lymphocytic leukemia (ALL), which is the most common type of cancer in children. It can also affect adults. Acute myeloid leukemia (AML), which is more common in older adults but can also affect children Chronic lymphocytic leukemia (CLL), which is one of the most common types of leukemia in adults. It often occurs during or after middle age. Chronic myeloid leukemia (CML), which usually occurs in adults during or after middle age What causes leukemia? Leukemia happens when there are changes in the genetic material (DNA) in bone marrow cells. The cause of these genetic changes is unknown. Who is at risk for leukemia? For the specific types, there are different factors which can raise your risk of getting that type. Overall, your risk of leukemia goes up as you age. It is most common over age 60. What are the symptoms of leukemia? Some of the symptoms of leukemia may include: Feeling tired Fever or night sweats Easy bruising or bleeding Weight loss or loss of appetite Petechiae, which are tiny red dots under the skin. They are caused by bleeding. Other leukemia symptoms can be different from type to type. Chromic leukemia may not cause symptoms at first. How is leukemia diagnosed? Your health care provider may use many tools to diagnose leukemia: A physical exam A medical history Blood tests, such as a complete blood count (CBC) Bone marrow tests. There are two main types - bone marrow aspiration and bone marrow biopsy. Both tests involve removing a sample of bone marrow and bone. The samples are sent to a lab for testing. Genetic tests to look for gene and chromosome changes Once the provider makes a diagnosis, there may be additional tests to see whether the cancer has spread. These include imaging tests and a lumbar puncture, which is a procedure to collect and test cerebrospinal fluid (CSF). What are the treatments for leukemia? The treatments for leukemia depend on which type you have, how severe the leukemia is, your age, your overall health, and other factors. Some possible treatments might include: Chemotherapy Radiation therapy Chemotherapy with stem cell transplant Targeted therapy, which uses drugs or other substances that attack specific cancer cells with less harm to normal cells NIH: National Cancer Institute

MalaCards based summary: Leukemia, also known as leukaemia, unspecified, without mention of remission, is related to myeloid leukemia and acute leukemia, and has symptoms including angina pectoris, chest pain and edema. An important gene associated with Leukemia is MIR27A (MicroRNA 27a), and among its related pathways/superpathways are NF-kappaB Signaling and Imatinib and chronic myeloid leukemia. The drugs Busulfan and Azacitidine have been mentioned in the context of this disorder. Affiliated tissues include myeloid, bone marrow and t cells, and related phenotypes are Increased HDAC inhibitor resistance and endocrine/exocrine gland

Disease Ontology: 11 A cancer that affects the blood or bone marrow characterized by an abnormal proliferation of blood cells.

Wikipedia: 75 Leukemia (also spelled leukaemia and pronounced /luːˈkiːmiːə/ loo-KEE-mee-ə) is a group of blood cancers... more...

Related Diseases for Leukemia

Diseases in the Leukemia family:

Chronic Leukemia Acute Leukemia
Subacute Leukemia

Diseases related to Leukemia via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 3387)
# Related Disease Score Top Affiliating Genes
1 myeloid leukemia 33.8 RUNX1T1 RUNX1 NPM1 LIF FLT3 ABL1
2 acute leukemia 33.6 TAL1 RUNX1T1 RUNX1 PBX1 FLT3
3 childhood leukemia 33.6 RUNX1T1 PBX1 NPM1 FLT3 ABL1
4 acute biphenotypic leukemia 33.4 RUNX1T1 FLT3 ABL1
5 juvenile myelomonocytic leukemia 33.4 RUNX1 NPM1 FLT3 ABL1
6 leukemia, chronic myeloid 33.3 TAL1 RUNX1 PML NPM1 MIR331 HOTAIR
7 chronic myelomonocytic leukemia 33.3 RUNX1 NPM1 FLT3 ABL1
8 precursor t-cell acute lymphoblastic leukemia 33.3 ZBTB16 TCL1A TAL1 LYL1 FLT3 ABL1
9 acute megakaryocytic leukemia 33.3 RUNX1T1 RUNX1 FLT3
10 childhood acute lymphocytic leukemia 33.3 RUNX1 FLT3 ABL1
11 leukemia, acute lymphoblastic 33.2 TCL1A TAL1 RUNX1 PBX1 MIR27A LYL1
12 core binding factor acute myeloid leukemia 33.2 RUNX1T1 NPM1 FLT3
13 acute myeloblastic leukemia with maturation 33.2 NPM1 FLT3
14 b-lymphoblastic leukemia/lymphoma 33.1 PBX1 FLT3 ABL1
15 acute myeloblastic leukemia without maturation 33.1 NPM1 FLT3
16 leukemia, chronic lymphocytic 33.1 TCL1A NPM1 NEAT1 MIR27A FLT3 ABL1
17 chronic leukemia 33.0 NPM1 FLT3 ABL1
18 acute promyelocytic leukemia 33.0 ZBTB16 RUNX1T1 RUNX1 PML NPM1 NEAT1
19 acute myelomonocytic leukemia 33.0 RUNX1 FLT3
20 adult acute lymphocytic leukemia 33.0 TAL1 PBX1 ABL1
21 childhood acute myeloid leukemia 32.9 RUNX1T1 NPM1 FLT3
22 myelodysplastic syndrome 32.8 RUNX1T1 RUNX1 NPM1 MIR27A FLT3 ABL1
23 acute myeloid leukemia with bcr-abl1 32.8 NPM1 FLT3 ABL1
24 b-cell adult acute lymphocytic leukemia 32.7 PBX1 ABL1
25 t-cell acute lymphoblastic leukemia 32.6 TCL1A TAL1 MIR27A LYL1 GAS5 ABL1
26 b-lymphoblastic leukemia/lymphoma with bcr-abl1 32.6 PBX1 ABL1
27 b-lymphoblastic leukemia/lymphoma with iamp21 32.5 PBX1 ABL1
28 central nervous system leukemia 32.5 PBX1 ABL1
29 acute myeloid leukemia with t(8;21)(q22;q22) translocation 32.5 RUNX1T1 RUNX1 FLT3
30 myeloid sarcoma 32.5 RUNX1T1 NPM1 FLT3
31 myelodysplastic/myeloproliferative neoplasm 32.4 NPM1 FLT3 ABL1
32 leukemia, acute myeloid 32.3 ZBTB16 TAL1 RUNX1T1 RUNX1 PML PBX1
33 childhood t-cell acute lymphoblastic leukemia 32.3 TAL1 LYL1
34 testicular leukemia 32.3 PBX1 ABL1
35 hematologic cancer 32.3 RUNX1T1 RUNX1 NPM1 MIR27A FLT3 ABL1
36 aggressive systemic mastocytosis 32.0 RUNX1 FLT3 ABL1
37 b-lymphoblastic leukemia/lymphoma with t(9;22)(q34.1;q11.2) 32.0 FLT3 ABL1
38 wilms tumor 1 31.7 RUNX1T1 NPM1 MIR27A FLT3 ABL1
39 lymphoma, non-hodgkin, familial 31.6 ZBTB16 TCL1A TAL1 NPM1 MIR331 MIR27A
40 myelofibrosis 31.6 RUNX1 NPM1 FLT3 CDKN2B-AS1
41 myeloma, multiple 31.3 TCL1A MIR27A LIF HOTAIR GAS5 FLT3
42 mantle cell lymphoma 31.1 TCL1A GAS5 FLT3 ABL1
43 blood platelet disease 31.1 RUNX1 FLT3 ABL1
44 bone marrow cancer 30.6 NPM1 MIR27A FLT3 ABL1
45 thyroid carcinoma 29.6 NEAT1 HOTAIR GAS5 CDKN2B-AS1
46 osteogenic sarcoma 29.5 NEAT1 HOTAIR GAS5 CDKN2B-AS1
47 glioma 29.3 NEAT1 HOTAIR GAS5 CDKN2B-AS1
48 oral squamous cell carcinoma 29.1 NEAT1 MIR331 MIR27A HOTAIR
49 melanoma 28.8 MIR331 MIR27A LIF HOTAIRM1 HOTAIR GAS5
50 retinitis pigmentosa 11 28.8 NEAT1 HOTAIRM1 HOTAIR GAS5 CDKN2B-AS1

Comorbidity relations with Leukemia via Phenotypic Disease Network (PDN):


Acute Cystitis Deficiency Anemia
Heart Disease Leukemia, Chronic Lymphocytic

Graphical network of the top 20 diseases related to Leukemia:



Diseases related to Leukemia

Symptoms & Phenotypes for Leukemia

UMLS symptoms related to Leukemia:


angina pectoris; chest pain; edema

GenomeRNAi Phenotypes related to Leukemia according to GeneCards Suite gene sharing:

25
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Increased HDAC inhibitor resistance GR00115-A-0 8.62 LIF LIFR

MGI Mouse Phenotypes related to Leukemia:

45
# Description MGI Source Accession Score Top Affiliating Genes
1 endocrine/exocrine gland MP:0005379 9.81 ABL1 FLT3 LIF LIFR NEAT1 PBX1
2 cellular MP:0005384 9.7 ABL1 FLT3 GAS5 LIF NEAT1 NPM1
3 skeleton MP:0005390 9.32 ABL1 FLT3 GAS5 HOTAIR LIF LIFR

Drugs & Therapeutics for Leukemia

Drugs for Leukemia (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 851)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Busulfan Approved, Investigational Phase 4 55-98-1 2478
2
Azacitidine Approved, Investigational Phase 4 320-67-2 9444
3
Decitabine Approved, Investigational Phase 4 2353-33-5 451668
4
Epirubicin Approved Phase 4 56420-45-2 41867
5
Morphine Approved, Investigational Phase 4 57-27-2 5288826
6
Letrozole Approved, Investigational Phase 4 112809-51-5 3902
7
Valganciclovir Approved, Investigational Phase 4 175865-60-8 64147
8
Dopamine Approved Phase 4 62-31-7, 51-61-6 681
9
Methylphenidate Approved, Investigational Phase 4 113-45-1 4158
10
Rasburicase Approved, Investigational Phase 4 134774-45-1
11
Cefepime Approved, Investigational Phase 4 88040-23-7 5479537
12
Cladribine Approved, Investigational Phase 4 4291-63-8 20279
13
Micafungin Approved, Investigational Phase 4 235114-32-6 477468
14
Teniposide Approved Phase 4 29767-20-2 34698 452548
15
Nicotine Approved Phase 4 54-11-5 942 89594
16
Bupropion Approved Phase 4 31677-93-7, 34841-39-9, 34911-55-2 444
17
Palonosetron Approved, Investigational Phase 4 119904-90-4, 135729-56-5 148211 6337614
18
Ceftazidime Approved Phase 4 78439-06-2, 72558-82-8 5481173
19
Ketamine Approved, Vet_approved Phase 4 6740-88-1, 1867-66-9 3821
20
Nitrous oxide Approved, Vet_approved Phase 4 10024-97-2 948
21
Granisetron Approved, Investigational Phase 4 109889-09-0 3510 5284566
22
Ketorolac Approved Phase 4 74103-06-3, 66635-83-4 3826
23
Simvastatin Approved Phase 4 79902-63-9 54454
24
Lidocaine Approved, Vet_approved Phase 4 137-58-6 3676
25
Prilocaine Approved Phase 4 721-50-6 4906
26
Venetoclax Approved, Investigational Phase 4 1257044-40-8 49846579
27
Lenograstim Approved, Investigational Phase 4 135968-09-1
28
Benzocaine Approved, Investigational Phase 4 1994-09-7, 94-09-7 2337
29
Tannic acid Approved Phase 4 1401-55-4 16129878 16129778
30
Amphotericin B Approved, Investigational Phase 4 1397-89-3 5280965
31
Chlorambucil Approved Phase 4 305-03-3 2708
32
Zidovudine Approved Phase 4 30516-87-1 35370
33
Acetylcysteine Approved, Investigational Phase 4 616-91-1 581 12035
34
Atomoxetine Approved Phase 4 82248-59-7, 83015-26-3 54841
35
Ergocalciferol Approved, Nutraceutical Phase 4 50-14-6 5280793
36
Calcifediol Approved, Nutraceutical Phase 4 19356-17-3 5283731
37
Uric acid Investigational Phase 4 69-93-2 1175
38 Thymoglobulin Phase 4
39
Ethylene Phase 4 74-85-1 6325
40 Estrogen Receptor Antagonists Phase 4
41 Estrogen Antagonists Phase 4
42 Aromatase Inhibitors Phase 4
43 Antidepressive Agents Phase 4
44 Cyclooxygenase Inhibitors Phase 4
45 Anti-Inflammatory Agents, Non-Steroidal Phase 4
46 Central Nervous System Stimulants Phase 4
47 Dopamine Uptake Inhibitors Phase 4
48 Dopamine Agents Phase 4
49
Vitamin D2 Phase 4 3249
50 Ergocalciferols Phase 4

Interventional clinical trials:

(show top 50) (show all 7184)
# Name Status NCT ID Phase Drugs
1 An Open-label,Multi-center,Prospective Study of Idarubicin and Etoposide Intensified Conditioning Regimen Allogeneic Hematopoietic Stem Cell Transplantation for Adult Acute Lymphoblastic Leukemia Unknown status NCT01873807 Phase 4 IDA;CTX;VP-16
2 Determinants of Mercaptopurine Toxicity in Paediatric Acute Lymphoblastic Unknown status NCT03920813 Phase 4 Mercaptopurine
3 The Combination of Lower Dosage of Chemotherapy With Tyrosine Kinase Inhibitor to Treat Newly Diagnosed ph+ Acute Lymphoblastic Leukemia Patients Unknown status NCT02690922 Phase 4 Dasatinib;prednisone;dexamethasone;methotrexate
4 Plasma Kinetics of Tablet and Liquid Formulations of 6-mercaptopurine in Childhood Acute Lymphoblastic Leukemia. Unknown status NCT01906671 Phase 4 Xaluprine;Puri-Nethol
5 Philadelphia -Negative High-risk Children Acute Lymphoblastic Leukemia(ALL) Treatment:Induction Therapy:Vincristine(V),Idarubicin(I),L-asparaginase(L),Dexamethasone(D);Consolidation:V+Daunorubicin(D)+L+D, Methotrexate,Cytarabine Unknown status NCT01990807 Phase 4 Idarubicin(IDA)
6 A Randomized Comparison of Fludarabine in Combination With Cytarabine Versus High -Dose Cytarabine in Post-remission Therapy for AML1-ETO Acute Myeloid Leukemia Unknown status NCT02024308 Phase 4 Fludarabine;Cytarabine
7 ASSESSMENT OF GH-IGF1 AXIS AND TO STUDY RESPONSE TO GH THERAPY IN CHILDREN WITH CML IN REMISSION HAVING GH DEFICIENCY Unknown status NCT01901666 Phase 4 Growth Hormone
8 Clinical Study of GD-2008 ALL Protocol for Childhood Acute Lymphoblastic Leukemia in Guangdong Province Unknown status NCT00846703 Phase 4 6-mercaptopurine, Methotrexate;6-mercaptopurine, Methotrexate, Vincristine, Dexamethasone
9 A Phase IV, Randomized Study to Evaluate the Safety and Efficacy of Idarubicin at Different Dosages Combined With Cytarabine as Induction Therapy for Newly Diagnosed Acute Myeloid Leukaemia Unknown status NCT02277847 Phase 4 Idarubicin(8mg/m2) and cytosine arabinoside;Idarubicin(10mg/m2), cytosine arabinoside
10 PEG-asparaginase During Two Treatment Courses in the Treatment of Childhood Acute Lymphoblastic Leukemia Unknown status NCT00192673 Phase 4 PEG-asparaginase
11 Early Tapering of Immunosuppressive Agents After Allogeneic Hematopoietic Stem Cell Transplantation Can Improve the Survival of Patients With Advanced Acute Myeloid Leukemia. Unknown status NCT03150134 Phase 4 Cyclosporine;routine reduction of immunosuppressive drugs(cyclosporine)
12 Low-dose Dasatinib as First-line Treatment for Chronic Myeloid Leukemia Unknown status NCT03216070 Phase 4 Dasatinib 50 MG
13 A Multicenter, Open-Label Study of Nipent, Cytoxan and Rituxan in Patients With Previously Untreated or Treated Chronic Lymphocytic Leukemia. Unknown status NCT00131313 Phase 4 Nipent, Cytoxan, Rituxan
14 Efficacy and Safety of Imatinib Mesylate as First-line Treatment for the Patients With Chronic Phase of Chronic Myeloid Leukemia Unknown status NCT02317159 Phase 4 Imatinib
15 Multicenter Study To Optimize Treatment in Elderly Patients (> 55 Years, No Upper Age Limit) With Acute Lymphoblastic Leukemia (GMALL Elderly 1/2003)(Amend 2) Unknown status NCT00198978 Phase 4 Cyclophosphamide;Dexamethasone / Prednisolone;Cytarabine;Idarubicin;Granulocyte-Colony-Stimulating Factor;Mercaptopurine;Methotrexate;Rituximab;HDARAC;Vincristine;Depocyte;Asparaginase
16 Medical Research Council Working Party on Leukaemia in Children UK National Acute Lymphoblastic Leukaemia (ALL) Trial: UKALL 2003 Unknown status NCT00222612 Phase 4 Standard childhood UK ALL protocol;Intensified treatment including Capizzi maintenance
17 Ma-Spore ALL 2010 Study Unknown status NCT02894645 Phase 4 Prednisolone;Dexamethasone;L-Asparaginase;Vincristine;Methotrexate;Daunorubicin;Doxorubicin;Cyclophosphamide;Cytarabine;6-Mercaptopurine;Thioguanine;Fludarabine;Imatinib
18 Multicenter Randomised Clinical Trial in Acute Myeloid Leukemia Treatment Based on Three Anthracyclines, Comparing Two Types of Consolidation With Different ARA-C Doses Followed by One Year Maintenance Unknown status NCT01587430 Phase 4 high dose ARA-C;standard dose ARA-C
19 Decitabine for Myelodysplastic Syndromes and Acute Myeloid Leukemia Before Allogeneic Hematopoietic Cell Transplantation Unknown status NCT01806116 Phase 4 decitabine
20 G-CSF Alone or Combination With GM-CSF on Prevention and Treatment of Infection in Children With Malignant Tumor: a Prospective, Multicentre, Randomised Controlled Trial Unknown status NCT02933333 Phase 4
21 Treatment of Relapsed Acute Promyelocytic Leukemia With Arsenic Trioxide (Phase IV Study) Unknown status NCT00196768 Phase 4 Arsenic trioxide;Trisenox
22 Combined Retinoic Acid,Arsenic Trioxide and Chemotherapy for Newly-diagnosed Acute Promyelocytic Leukemia: Chinese National Multi-center Randomized Study Unknown status NCT01987297 Phase 4 ATRA+Arsenic;ATRA+Chemo
23 Intensification Therapy of Mature B-ALL, Burkitt and Burkitt Like and Other High Grade Non-Hodgkin's Lymphoma in Adults Unknown status NCT00797810 Phase 4 Rituximab
24 Multicenter, PhaseⅣ, Open Label Trial of Nilotinib in Adult Patients Diagnosed Philadelphia Chromosome Positive(Ph+) Chronic Myeloid Leukemia in CP/AP Intolerant to Dasatinib Unknown status NCT02389920 Phase 4 Nilotinib
25 AIDA2000 - Risk-Adapted Therapy for Patients With Acute Promyelocytic Leukemia(APL) Unknown status NCT00180128 Phase 4 all-trans retinoid acid;idarubicin;mitoxantrone;daunorubicin;cytarabine
26 Treatment Plan for Hematologic Malignancies Using Intravenous Busulfan and Cyclophosphamide Instead of Total Boby Irradiation (TBI) and Cyclophosphamide to Examine Results, Success and Side Effects of Treatment With Chemotherapy Only, as a Preparative Therapy for Patients With Cord Blood Transplants Unknown status NCT01339988 Phase 4 Busulfan/Cyclophosphamide
27 The Outcomes of ICSI Cycles With and Without Letrozole and Its Correlation With Mid-luteal Endometrial αvβ3 Integrin and Leukemia Inhibitory Factor Unknown status NCT04159649 Phase 4 Letrozole 2.5Mg Tablet;Gonadotropins
28 Safety and Efficacy Study of Busulfan/FLAG Conditioning Regimen in Patients With Relapsed/Refractory Acute Leukemia Undergoing Allogeneic Peripheral Blood Stem Cell Transplantation Unknown status NCT02784561 Phase 4 Busulfan (Zhejiang Otsuka Pharmaceutical Co. Ltd);Cytarabine(Actavis Italy S.p.A);Fludarabine (Bayer);granulocyte colony-stimulating factor (KirinKunpeng);rabbit ATG(Sanofi/Genzyme)
29 Treatment of Elderly Patients (>60 Years) With Acute Myeloblastic Leukemia or Advanced MDS (RAEB-T): An Open Randomized Study to Test the Efficacy of G-CSF-Priming and a Feasibility Trial of Dose-Reduced Allogeneic Transplantation and of Autologous Stem Cell Transplantation Unknown status NCT00199147 Phase 4 Cytarabine;Etoposide;Idarubicin;G-CSF;Fludarabine
30 A Prospective Single Center Study of Prevention and Treatment of Differentiation Syndrome in Patients With Acute Promyelocytic Leukemia Unknown status NCT04446806 Phase 4 Ruxolitinib
31 Interferon for the Intervention of Molecular Relapse in t (8; 21) AML After Allo-HSCT Unknown status NCT02027064 Phase 4 Interferon-alpha
32 Self-control Trial to Evaluate the Role of Aprepitant in the Prophylaxis of Post-lumbar-punture-headache (PLPH) Unknown status NCT02347878 Phase 4 Aprepitant
33 A Randomized,Open,Multicenter and Prospective Study of the Optimized Dose of Anti-Thymoglobuline in Haploidentical Allogeneic Stem Cell Transplantation Unknown status NCT03190733 Phase 4 ATG
34 A Clinical Trial of Decitabine Combined With CODOX-M/IVAC in Relapsed or Refractory T-lymphoblastic Lymphoma Unknown status NCT03558412 Phase 4 Decitabine
35 Hematology , Shanghai Jiaotong University Affiliated Shanghai First People's Hospital, Shanghai, China Unknown status NCT02938741 Phase 4 Anti-human Thymoglobulin;Placebo
36 A Randomized Open-Label Trial of Posaconazole Versus Micafungin for Prophylaxis Against Invasive Fungal Infections During Neutropenia in Patients Undergoing Chemotherapy for Acute Myelogenous Leukemia, Acute Lymphocytic Leukemia or Myelodysplastic Syndrome Completed NCT01200355 Phase 4 micafungin;posaconazole
37 Randomised Multicentre Phase IV Study to Compare Glivec® (Imatinib Mesylate, STI571) in Monotherapy Versus Glivec® in Combination With Interferon Alpha at Low Doses in the Treatment of Newly-Diagnosed Chronic-Phase Chronic Myeloid Leukaemia Completed NCT00390897 Phase 4 Glivec;Interferon
38 Efficacy and Safety of Dasatinib in the First-line Treatment of Newly Diagnosed Chronic-Phase Chronic Myeloid Leukemia (CML-CP) Completed NCT04925141 Phase 4 Dasatinib Tablets
39 A Phase IV, Open-label, Multicenter Study of Dasatinib in Chronic-Phase Chronic Myeloid Leukemia (CP-CML) Patients With Chronic, Low-grade Non-Hematologic Toxicity to Imatinib Completed NCT01660906 Phase 4 Dasatinib
40 A Phase 4 Study of Nilotinib in Korean Patients With Philadelphia Chromosome-positive Chronic Myeloid Leukemia in Chronic Phase Completed NCT03332511 Phase 4 Nilotinib
41 An Open-label, Multicenter Study of Treatment With Nilotinib in Adult Patients With Imatinib - Resistant or - Intolerant Chronic Myeloid Leukemia in Blast Crisis, Accelerated Phase or Chronic Phase Completed NCT00786812 Phase 4 Nilotinib
42 LAL-Ph-2000: Treatment of Acute Lymphoblastic Leukemia Chromosome Philadelphia Positive Completed NCT00526305 Phase 4 Vincristine;Daunorubicin;Prednisone;L-Asparaginase;Mitoxantrone;Cytosine Arabinoside;Hydrocortisone;Mercaptopurine;Cyclophosphamide;Dexamethasone
43 Pulses of Vincristine and Dexamethasone During Maintenance in BFM Protocols for Children With Intermediate-Risk Acute Lymphoblastic Leukemia Completed NCT00411541 Phase 4 vincristine;dexamethasone
44 FLAG-IDA Chemotherapy Induction Follow by Intensive Chemotherapy Postremission +/- Autologous Hemopoietic Stem Cell Transplantation or Bone Marrow Transplantation in Patients With High Risk Myelodysplastic Syndromes or Secondary Acute Myeloblastic Leukemia. Completed NCT00487448 Phase 4 Fludarabine;Cytarabine;G-CSF;Idarubicin
45 PETHEMA-LAM99:Treatment of the Acute Myeloblastic Leukaemia in Patients Over 65 Years Completed NCT00464217 Phase 4 ARA-C;Idarubicin;Leucomax
46 PETHEMA LAL-RI/96: Treatment for Patients With Standard Risk Acute Lymphoblastic Leukemia Completed NCT00494897 Phase 4 Asparaginase;Cyclophosphamide;Cytarabine;Daunorubicin;Mercaptopurine;Prednisone;Vincristine;Methotrexate
47 LAL-AR-N-2005: Study Treatment for Children High Risk Acute Lymphoblastic Leukemia Completed NCT00526409 Phase 4 Prednisolone;Daunorubicin;Vincristine;L-Asparaginase;Cyclophosphamide;Methotrexate;Cytosine Arabinoside
48 FLAT: Fludarabine, Cytarabine and Topotecan in Treating Patients With Refractory or Relapsed Acute Myeloid Leukemia Completed NCT00488709 Phase 4 Topotecan;Fludarabine;Cytarabine
49 Treatment of High Risk Adult Acute Lymphoblastic Leukemia Completed NCT00853008 Phase 4 Vincristine;Daunorubicin;Prednisone;Mitoxantrone;Cytosine Arabinoside;Dexamethasone;Methotrexate (MTX);Cytarabine;ASP;Mercaptopurine;Teniposide;Hydrocortisone
50 Glivec in Pediatric Chronic Myeloid Leukemia (CML) Completed NCT00845221 Phase 4 Imatinib mesylate 100 mg (Glivec)

Search NIH Clinical Center for Leukemia

Inferred drug relations via UMLS 71 / NDF-RT 50 :


Cytarabine
Cytarabine liposome
irinotecan
Irinotecan hydrochloride
Isotretinoin
Methotrexate
Methotrexate Sodium
Pipobroman
Vincristine
Vincristine Sulfate

Cell-based therapeutics:


LifeMap Discovery
Data from LifeMap, the Embryonic Development and Stem Cells Database
Read about Leukemia cell therapies at LifeMap Discovery.

Cochrane evidence based reviews: leukemia

Genetic Tests for Leukemia

Genetic tests related to Leukemia:

# Genetic test Affiliating Genes
1 Leukemia 28

Anatomical Context for Leukemia

Organs/tissues related to Leukemia:

MalaCards : Myeloid, Bone Marrow, T Cells, Bone, Nk Cells, B Cells, Skin

Publications for Leukemia

Articles related to Leukemia:

(show top 50) (show all 50433)
# Title Authors PMID Year
1
CT Scans and Cancer Risks: A Systematic Review and Dose-response Meta-analysis. 41
36451138 2022
2
Leukemia can be Effectively Early Predicted in Routine Physical Examination with the Assistance of Machine Learning Models. 41
36465253 2022
3
Global disease burden and trends of leukemia attributable to occupational risk from 1990 to 2019: An observational trend study. 41
36452945 2022
4
Down-regulated miR-331-5p and miR-27a are associated with chemotherapy resistance and relapse in leukaemia. 46
21070600 2011
5
Modeling T-cell acute lymphoblastic leukemia induced by the SCL and LMO1 oncogenes. 53 62
20516195 2010
6
Involvement of p38 MAPK- and JNK-modulated expression of Bcl-2 and Bax in Naja nigricollis CMS-9-induced apoptosis of human leukemia K562 cells. 53 62
20144638 2010
7
Activation of Ras-dependent Elk-1 activity by MLL-AF4 family fusion oncoproteins. 53 62
20362031 2010
8
Prognostic implications of mutations and expression of the Wilms tumor 1 (WT1) gene in adult acute T-lymphoblastic leukemia. 53 62
20435628 2010
9
Leukemia inhibitory factor is dysregulated in the endometrium and uterine flushing fluid of patients with adenomyosis during implantation window. 53 62
19361790 2010
10
Mcl1 haploinsufficiency protects mice from Myc-induced acute myeloid leukemia. 53 62
20484815 2010
11
LLL-3, a STAT3 inhibitor, represses BCR-ABL-positive cell proliferation, activates apoptosis and improves the effects of Imatinib mesylate. 53 62
19701750 2010
12
Natural-killer cell amplification for adoptive leukemia relapse immunotherapy: comparison of three cytokines, IL-2, IL-15, or IL-7 and impact on NKG2D, KIR2DL1, and KIR2DL2 expression. 53 62
20172016 2010
13
Cucurbitacin E as a new inhibitor of cofilin phosphorylation in human leukemia U937 cells. 53 62
20347305 2010
14
Nup98-homeodomain fusions interact with endogenous Nup98 during interphase and localize to kinetochores and chromosome arms during mitosis. 53 62
20237156 2010
15
Genetic variation in the folate metabolic pathway and risk of childhood leukemia. 53 62
20101025 2010
16
Wilms' tumor gene 1 protein represses the expression of the tumor suppressor interferon regulatory factor 8 in human hematopoietic progenitors and in leukemic cells. 53 62
20237505 2010
17
Linkage of the potent leukemogenic activity of Meis1 to cell-cycle entry and transcriptional regulation of cyclin D3. 53 62
20237320 2010
18
Expression pattern of the septin gene family in acute myeloid leukemias with and without MLL-SEPT fusion genes. 53 62
19748670 2010
19
Mixed lineage leukemia: a structure-function perspective of the MLL1 protein. 53 62
20236310 2010
20
Salinomycin overcomes ABC transporter-mediated multidrug and apoptosis resistance in human leukemia stem cell-like KG-1a cells. 53 62
20350531 2010
21
Mixed lineage leukemia: histone H3 lysine 4 methyltransferases from yeast to human. 53 62
20236312 2010
22
c-Abl mediates endothelial apoptosis induced by inhibition of integrins alphavbeta3 and alphavbeta5 and by disruption of actin. 53 62
20124512 2010
23
STAT5 in B cell development and leukemia. 53 62
20227268 2010
24
Identification of Zfp521/ZNF521 as a cooperative gene for E2A-HLF to develop acute B-lineage leukemia. 53 62
20062079 2010
25
MLL-rearranged B lymphoblastic leukemias selectively express the immunoregulatory carbohydrate-binding protein galectin-1. 53 62
20332322 2010
26
Sp1/NFkappaB/HDAC/miR-29b regulatory network in KIT-driven myeloid leukemia. 53 62
20385359 2010
27
The Bcl-2 homology domain 3 mimetic ABT-737 targets the apoptotic machinery in acute lymphoblastic leukemia resulting in synergistic in vitro and in vivo interactions with established drugs. 53 62
20038611 2010
28
Ordering human CD34+CD10-CD19+ pre/pro-B-cell and CD19- common lymphoid progenitor stages in two pro-B-cell development pathways. 53 62
20231472 2010
29
Cucurbitacin B inhibits STAT3 and the Raf/MEK/ERK pathway in leukemia cell line K562. 53 62
19700240 2010
30
Functional characterization of high levels of meningioma 1 as collaborating oncogene in acute leukemia. 53 62
20072157 2010
31
Salicylic acid based small molecule inhibitor for the oncogenic Src homology-2 domain containing protein tyrosine phosphatase-2 (SHP2). 53 62
20170098 2010
32
Analysis of Ikaros family splicing variants in human hematopoietic lineages. 53 62
20432734 2010
33
Leukemia inhibitory factor receptor (LIFR) is detected as a novel suppressor gene of hepatocellular carcinoma using double-combination array. 53 62
19733004 2010
34
MEIS proteins as partners of the TLX1/HOX11 oncoprotein. 53 62
19559479 2010
35
Xenotropic murine leukemia virus-related virus is susceptible to AZT. 53 62
19959199 2010
36
The Lmo2 oncogene initiates leukemia in mice by inducing thymocyte self-renewal. 53 62
20093438 2010
37
c-Myb binds MLL through menin in human leukemia cells and is an important driver of MLL-associated leukemogenesis. 53 62
20093773 2010
38
Acute T-cell leukemias remain dependent on Notch signaling despite PTEN and INK4A/ARF loss. 53 62
20008304 2010
39
Malignant transformation of Slp65-deficient pre-B cells involves disruption of the Arf-Mdm2-p53 tumor suppressor pathway. 53 62
20008789 2010
40
GAS6/Mer axis regulates the homing and survival of the E2A/PBX1-positive B-cell precursor acute lymphoblastic leukemia in the bone marrow niche. 53 62
19922767 2010
41
Favorable prognostic impact of NPM1 mutations in older patients with cytogenetically normal de novo acute myeloid leukemia and associated gene- and microRNA-expression signatures: a Cancer and Leukemia Group B study. 53 62
20026798 2010
42
STAT3 is a substrate of SYK tyrosine kinase in B-lineage leukemia/lymphoma cells exposed to oxidative stress. 53 62
20133729 2010
43
AFF4, a component of the ELL/P-TEFb elongation complex and a shared subunit of MLL chimeras, can link transcription elongation to leukemia. 53 62
20159561 2010
44
Constitutively active AKT depletes hematopoietic stem cells and induces leukemia in mice. 53 62
20008787 2010
45
Impact of breast cancer resistance protein on cancer treatment outcomes. 53 62
19949928 2010
46
Identification of two critically deleted regions within chromosome segment 7q35-q36 in EVI1 deregulated myeloid leukemia cell lines. 53 62
20084277 2010
47
Abnormal expression of P2X family receptors in Chinese pediatric acute leukemias. 53 62
19919827 2010
48
PCI-24781, a Novel Hydroxamic Acid HDAC Inhibitor, Exerts Cytotoxicity and Histone Alterations via Caspase-8 and FADD in Leukemia Cells. 53 62
20145726 2010
49
Linalool preferentially induces robust apoptosis of a variety of leukemia cells via upregulating p53 and cyclin-dependent kinase inhibitors. 53 62
19922762 2010
50
Up-regulation of survivin by the E2A-HLF chimera is indispensable for the survival of t(17;19)-positive leukemia cells. 53 62
19887369 2010

Variations for Leukemia

Copy number variations for Leukemia from CNVD:

6 (show all 44)
# CNVD ID Chromosome Start End Type Gene Symbol CNVD Disease
1 19383 1 150034000 245120000 Amplification Leukemia
2 33637 1 46800000 50700000 Loss Leukemia
3 44329 10 55250865 57057708 Rearrangement PCDH15 Leukemia
4 62297 12 10760000 26234000 Amplification Leukemia
5 64439 12 12800000 14800000 Gain SLC2A14 Leukemia
6 64440 12 12800000 14800000 Gain SLC2A3 Leukemia
7 69764 12 56263000 69037000 Amplification Leukemia
8 69765 12 56263000 69037000 Amplification Leukemia
9 74441 13 107000000 115169878 Loss Leukemia
10 77064 13 39703000 40042000 Amplification Leukemia
11 86548 14 62100000 64800000 Gain SYNE2 Leukemia
12 109053 17 24000000 81195210 Copy number SLC2A1 Leukemia
13 112810 17 41159000 78182000 Amplification Leukemia
14 127115 19 26500000 59128983 Gain Leukemia
15 134399 2 10062000 11645000 Amplification Leukemia
16 138038 2 15720000 16465000 Amplification Leukemia
17 138662 2 16873000 60356000 Amplification Leukemia
18 138663 2 16873000 60356000 Amplification Leukemia
19 147406 2 64333000 65547000 Amplification Leukemia
20 153044 20 33909000 62377000 Amplification Leukemia
21 156917 20 9002000 17491000 Amplification Leukemia
22 159831 21 45112000 46015000 Amplification Leukemia
23 161203 22 17722000 17723000 Amplification Leukemia
24 165015 22 41000000 44200000 Gain RRP7A Leukemia
25 165016 22 41000000 44200000 Gain SERHL Leukemia
26 172851 3 18696000 18818000 Amplification Leukemia
27 173075 3 189413414 190080135 Translate LPP Leukemia
28 191719 6 1 60500000 Loss of mismatch HLA-A Leukemia
29 191720 6 1 60500000 Loss of mismatch HLA-B Leukemia
30 191721 6 1 60500000 Loss of mismatch HLA-C Leukemia
31 200024 5 48400000 180915260 Deletion Leukemia
32 204999 6 118500000 171115067 Gain Leukemia
33 205139 6 121263000 130387000 Deletion Leukemia
34 206061 6 135502452 135540311 Gain MYB Leukemia
35 215006 6 70000000 114600000 Loss Leukemia
36 226598 7 59900000 159138663 Deletion Leukemia
37 246206 9 117700000 122500000 Loss Leukemia
38 250022 9 19900000 25600000 Deletion CDKN2A Leukemia
39 250028 9 19900000 25600000 Loss CDKN2A Leukemia
40 250692 9 21957750 21984490 Deletion CDKN2A Leukemia
41 253950 9 49000000 141213431 Deletion Leukemia
42 254016 9 50700000 114900000 Loss Leukemia
43 304060 5 23543480 23564463 Mutation PRDM9 Leukemia
44 304367 7 1780332 38257086 Deletion DOCK4 Leukemia

Expression for Leukemia

Search GEO for disease gene expression data for Leukemia.

Pathways for Leukemia

GO Terms for Leukemia

Biological processes related to Leukemia according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 cellular senescence GO:0090398 9.8 PML NPM1 ABL1
2 positive regulation of fibroblast proliferation GO:0048146 9.73 PML LIF ABL1
3 leukemia inhibitory factor signaling pathway GO:0048861 9.71 LIFR LIF
4 regulation of cell population proliferation GO:0042127 9.67 TAL1 PBX1 FLT3 ABL1
5 positive regulation of extracellular matrix organization GO:1903055 9.46 RUNX1 ABL1
6 myeloid cell differentiation GO:0030099 9.35 ZBTB16 TAL1 PML
7 hemopoiesis GO:0030097 9.23 ZBTB16 TAL1 RUNX1 FLT3

Sources for Leukemia

2 CDC
6 CNVD
8 Cosmic
9 dbSNP
10 DGIdb
16 EFO
17 ExPASy
18 FMA
19 GARD
27 GO
28 GTR
29 HMDB
30 HPO
31 ICD10
32 ICD10 via Orphanet
33 ICD11
34 ICD9CM
35 IUPHAR
36 LifeMap
38 LOVD
40 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
52 NINDS
53 Novoseek
55 ODiseA
56 OMIM via Orphanet
57 OMIM® (Updated 08-Dec-2022)
61 PubChem
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....